公开(公告)号：US20150010475A1

公开(公告)日：2015-01-08

申请号：US14369741

申请日：2012-12-31

Applicant: STC. UNM ,  SANDIA CORPORATION

Inventor： C. Jeffrey Brinker ,  David S. Peabody ,  Walker Kip Wharton ,  Bryce Chackerian ,  Carlee Erin Ashley ,  Cheryl L. Willman ,  Eric C. Carnes ,  Katherine Epler ,  Robert Eric Castillo

IPC: A61K47/48 ,  C12N15/113 ,  C12N15/11 ,  C07K7/06 ,  A61K31/704

CPC classification number: A61K31/704 ,  A61K47/62 ,  A61K47/64 ,  A61K47/6911 ,  C07K7/06 ,  C12N15/111 ,  C12N15/113

Abstract: The present invention relates to the use of which are attached or anchored phospholipid biolayers further modified by CRLF-2 and CD 19 binding peptides which may be used for delivering pharmaceutical cargos, to cells expressing CRLF-2 and CD 19, thereby treating cancer, in particular, acute lymphoblastic leukemia (ALL), including (B-precursor acute lymphoblastic leukemia (B-ALL). Novel CRLF-2 binding peptides and CLRF-2 and CD19-binding viral-like particles (VLPs) useful in the treatment of cancer, including ALL are also provided.

Abstract translation: 本发明涉及其用途，其可用于将可用于递送药物载体的CRLF-2和CD19结合肽进一步修饰的磷脂生物层结合到表达CRLF-2和CD19的细胞中，从而治疗癌症 特别是急性淋巴细胞白血病（ALL），包括（B-前体急性成淋巴细胞白血病（B-ALL）），用于治疗癌症的新型CRLF-2结合肽和CLRF-2和CD19结合病毒样颗粒（VLP） ，也包括ALL。

公开(公告)号：US20190201540A1

公开(公告)日：2019-07-04

申请号：US16304020

申请日：2017-05-24

Applicant: Bryce Chackerian ,  Alan Remaley ,  Ingrid Lindquist ,  Ingrid Lindquist ,  STC UNM

Inventor： Bryce Chackerian ,  Alan Ramaley ,  Ingrid Lindquist

IPC: A61K47/64 ,  A61K39/00 ,  A61K39/12 ,  A61K47/69 ,  C07K14/775 ,  A61P3/06 ,  C12N15/85

CPC classification number: A61K47/646 ,  A61K39/0005 ,  A61K39/12 ,  A61K45/06 ,  A61K47/6901 ,  A61K2039/62 ,  A61P3/06 ,  C07K14/775 ,  C12N15/85 ,  C12N2795/18123

Abstract: This disclosure describes immunogens, compositions, and methods for treating dyslipidemia. The immunogen included an ApoC3-derived peptide linked to a bacteriophage virus like particle (VLP) immunogenic carrier. The ApoC3 immunogen can be administered to a subject having, or at risk of having, dyslipidemia. The ApoC3 immunogen may be administered alone or co-administered with an additional dyslipidemia therapeutic agent.

公开(公告)号：US20160354459A1

公开(公告)日：2016-12-08

申请号：US15176396

申请日：2016-06-08

Applicant: STC. UNM

Inventor： David S. Peabody ,  Bryce Chackerian

IPC: A61K39/12 ,  C12N7/00

CPC classification number: A61K39/12 ,  A61K39/07 ,  A61K2039/5256 ,  A61K2039/5258 ,  C12N7/00 ,  C12N15/1037 ,  C12N2710/20022 ,  C12N2710/20034 ,  C12N2740/16034 ,  C12N2740/16134 ,  C12N2795/16021 ,  C12N2795/16022 ,  C12N2795/16023 ,  C12N2795/16042 ,  C12N2795/18023 ,  C40B40/08

Abstract: The present invention relates to a system and method for controlling peptide display valency on virus-like particles (VLPs), especially including MS2 VLPs. In this method, large amounts of wild-type and low quantities of single-chain dimer coat proteins may be produced from a single RNA. Valency is controlled in immunogen (vaccine) production by providing a system that allows the production of large amounts of wild-type and low quantities of single-chain dimer coating proteins from a single RNA, allowing facile adjustment of display valency levels on VLPs, especially MS2 VLPS over a wide range, from few than one—on average—to as many as ninety per particle. This facilitates the production of immunogens and vaccines, including VLPs exhibiting low valency. Nucleic acid constructs useful in the expression of virus-like particles are disclosed, comprised of a coat polypeptide of MS2 modified by insertion of a heterologous peptide, wherein the heterologous peptide is displayed on the virus-like particle and encapsidates MS2 niRNA. Nucleic acid constructs are also disclosed which are useful in the expression of virus-like particles comprised of a coat polypeptide of PP7 modified by insertion of a heterologous peptide, wherein the heterologous peptide is displayed on the virus-like particle and encapsidates PP7 mRNA.

Abstract translation: 本发明涉及一种用于控制病毒样颗粒（VLPs），特别是包括MS2 VLP的肽显示效价的系统和方法。 在该方法中，可以从单个RNA产生大量野生型和低量的单链二聚体外壳蛋白。 通过提供允许从单个RNA产生大量野生型和少量单链二聚体包被蛋白质的系统，允许轻度调整VLP上的显示剂价位水平，特别是 MS2 VLPS在广泛的范围内，从一个平均至少一个到每个粒子多达九十个。 这有助于免疫原和疫苗的生产，包括显示低效价的VLP。 公开了可用于病毒样颗粒表达的核酸构建物，其由通过插入异源肽修饰的MS2的外壳多肽组成，其中异源肽显示在病毒样颗粒上并包裹MS2nRNA。 还公开了核酸构建体，其可用于由通过插入异源肽修饰的PP7的外壳多肽组成的病毒样颗粒的表达，其中异源肽显示在病毒样颗粒上并包裹PP7 mRNA。

公开(公告)号：US20180050097A1

公开(公告)日：2018-02-22

申请号：US15561130

申请日：2016-03-25

Applicant: STC. UNM

Inventor： Kiran Bhaskar ,  Nicole Maphis ,  David S. Peabody ,  Bryce Chackerian ,  Julianne Peabody ,  Erin Crossey

IPC: A61K39/00 ,  A01K67/027 ,  C12N7/00

CPC classification number: A61K39/0007 ,  A01K67/0278 ,  A01K2217/056 ,  A01K2217/072 ,  A01K2217/075 ,  A01K2217/15 ,  A01K2227/105 ,  A01K2267/0306 ,  A01K2267/0312 ,  A01K2267/0318 ,  A01K2267/0368 ,  A61K2039/5258 ,  A61K2039/575 ,  C12N7/00 ,  C12N2795/18123 ,  C12N2795/18134 ,  C12N2795/18171

Abstract: This disclosure describes, in one aspect, immunogens effective for treating and/or diagnosing tauopathy, and immunotherapeutic compositions and methods involving those immunogens. Generally, the immunogen includes an antigen presentation component and a microtubule-associated tau protein (MAPT) component linked to at least a portion of the antigen presentation component. This disclosure describes, in another aspect, a transgenic mouse. Generally, the transgenic mouse possesses brain cells that have a polynucleotide that encodes human microtubule-associated protein tau (MAPT). The polynucleotide further exhibits a deletion of at least a portion of endogenous mouse MAPT. The transgenic mouse also includes a forebrain neuron-specific deletion of a polynucleotide that encodes Myeloid Differentiation Primary Response Gene 88 (MyD88). In a further aspect, this disclosure describes a method of producing the transgenic mouse.

公开(公告)号：US20150164798A1

公开(公告)日：2015-06-18

申请号：US14627739

申请日：2015-02-20

Applicant: STC.UNM ,  SANDIA CORPORATION

Inventor： C. Jeffrey Brinker ,  Carlee Erin Ashley ,  Xingmao Jiang ,  Juewen Liu ,  David S. Peabody ,  Walker Richard Wharton ,  Eric Carnes ,  Bryce Chackerian ,  Cheryl L. Willman

IPC: A61K9/127 ,  A61K31/704

CPC classification number: A61K9/127 ,  A61K9/1277 ,  A61K9/5115 ,  A61K9/5123 ,  A61K31/513 ,  A61K31/575 ,  A61K31/704 ,  A61K33/24 ,  A61K49/005

Abstract: Various embodiments provide materials and methods for synthesizing protocells for use in targeted delivery of cargo components to cancer cells. In one embodiment, the lipid bilayer can be fused to the porous particle core to form a protocell. The lipid bilayer can be modified with targeting ligands or other ligands to achieve targeted delivery of cargo components that are loaded within the protocell to a target cell, e.g., a type of cancer. Shielding materials can be conjugated to the surface of the lipid bilayer to reduce undesired non-specific binding.

Abstract translation: 各种实施方案提供用于合成原细胞以用于向癌细胞靶向递送货物组分的材料和方法。 在一个实施方案中，脂质双层可以与多孔颗粒核心融合以形成原细胞。 脂质双层可以用靶向配体或其他配体进行修饰，以实现载体在原细胞内的货物组分的靶向递送到靶细胞，例如一种类型的癌症。 屏蔽材料可以结合到脂质双层的表面以减少不期望的非特异性结合。

公开(公告)号：US09480653B2

公开(公告)日：2016-11-01

申请号：US14627739

申请日：2015-02-20

Applicant: STC.UNM ,  SANDIA CORPORATION

Inventor： C. Jeffrey Brinker ,  Carlee Erin Ashley ,  Xingmao Jiang ,  Juewen Liu ,  David S. Peabody ,  Walker Richard Wharton ,  Eric Carnes ,  Bryce Chackerian ,  Cheryl L. Willman

IPC: A61K9/56 ,  A61K9/127 ,  A61K9/51 ,  A61K49/00 ,  A61K31/575 ,  A61K31/513 ,  A61K33/24 ,  A61K31/704

CPC classification number: A61K9/127 ,  A61K9/1277 ,  A61K9/5115 ,  A61K9/5123 ,  A61K31/513 ,  A61K31/575 ,  A61K31/704 ,  A61K33/24 ,  A61K49/005

Abstract: Various embodiments provide materials and methods for synthesizing protocells for use in targeted delivery of cargo components to cancer cells. In one embodiment, the lipid bilayer can be fused to the porous particle core to form a protocell. The lipid bilayer can be modified with targeting ligands or other ligands to achieve targeted delivery of cargo components that are loaded within the protocell to a target cell, e.g., a type of cancer. Shielding materials can be conjugated to the surface of the lipid bilayer to reduce undesired non-specific binding.

公开(公告)号：US20150320681A1

公开(公告)日：2015-11-12

申请号：US14797487

申请日：2015-07-13

Applicant: STC.UNM ,  SANDIA CORPORATION

Inventor： C. Jeffrey Brinker ,  Carlee Erin Ashley ,  Xingmao Jiang ,  Juewen Liu ,  David S. Peabody ,  Walker Richard Wharton ,  Eric Carnes ,  Bryce Chackerian ,  Cheryl L. Willman

IPC: A61K9/127 ,  A61K33/24 ,  A61K31/704 ,  A61K31/513 ,  A61K49/00 ,  A61K31/575

CPC classification number: A61K9/127 ,  A61K9/1277 ,  A61K9/5115 ,  A61K9/5123 ,  A61K31/513 ,  A61K31/575 ,  A61K31/704 ,  A61K33/24 ,  A61K49/005

Abstract: Various embodiments provide materials and methods for synthesizing protocells for use in targeted delivery of cargo components to cancer cells. In one embodiment, the lipid bilayer can be fused to the porous particle core to form a protocell. The lipid bilayer can be modified with targeting ligands or other ligands to achieve targeted delivery of cargo components that are loaded within the protocell to a target cell, e.g., a type of cancer. Shielding materials can be conjugated to the surface of the lipid bilayer to reduce undesired non-specific binding.